• (S)-(+)-Methoprene: Separating JH Supply from Signal

  2026-09-24

  See how (S)-(+)-Methoprene, a juvenile hormone analog, can help distinguish changes in hormone production from changes in hormone response. A recent locust study reveals why this separation matters when interpreting vitellogenesis, miRNA regulation, and developmental assays.

• SB-505124 Hydrochloride: Practical Research Workflows

  2026-09-24

  Use SB-505124 hydrochloride to test ALK4/5/7-dependent TGF-β/activin signaling in fibrosis-focused experiments, with practical readouts from Smad phosphorylation to CTGF and α-SMA. The workflows also show how to connect pathway perturbation to cell-mechanics assays without implying that this inhibitor has been shown to alter the MRTFA–KCNMB1 axis.

• CHK1 Inhibition in Breast Cancer: ER/PR Status Matters

  2026-09-23

  This study shows that CHK1 inhibition has different effects across breast cancer subtypes: it sensitizes ER−/PR−/HER2− cells to adriamycin, but does not improve adriamycin toxicity in ER+/PR+/HER2− cells. The work links these differences to distinct cell-cycle and apoptosis pathways, supporting receptor status as a factor in designing preclinical CHK1-targeted strategies.

• HOXC9, AKT/mTOR, and ESCC Apoptosis

  2026-09-23

  A 2026 study identifies HOXC9 as a potential upstream regulator of esophageal squamous cell carcinoma progression, linking its expression to enhanced proliferation and reduced mitochondria-dependent apoptosis through AKT/mTOR signaling. The work combines patient-tissue analysis, genetic perturbation, transcriptomics, pathway inhibition, and xenograft experiments, while also highlighting the need for validation across clinical and molecular subtypes.

• I-BET-762: BET Inhibitor Workflow for Ferroptosis

  2026-09-22

  I-BET-762 provides a practical way to connect BET-dependent transcription with ROS accumulation, FSP1 control, and ferroptosis sensitivity. This workflow translates published combination data into reproducible assay design for cancer biology research, while preserving a separate path for inflammation and LPS-responsive gene studies.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-09-22

  Tamoxifen combines temporal control of conditional gene deletion with broad utility in breast cancer research and pathway-focused cell assays. This guide connects practical CreER workflows to the PINK1–mitochondrial iron findings while emphasizing formulation, controls, and interpretation limits.

• BCECF for Extracellular pH Assays

  2026-09-21

  BCECF converts extracellular acid–base changes into a quantitative dual-excitation ratio for ion transport, metabolism, and efferocytosis workflows. Its cell-impermeant design helps distinguish extracellular microenvironment changes from intracellular signaling in macrophage and neuropathic pain research.

• BMP4-GPX4 Protects RGCs in NMDA Glaucoma

  2026-09-21

  The reference study identifies the BMP4–GPX4 axis as a potential link between retinal ganglion cell protection, ferroptosis control, and retinal stem cell differentiation in an NMDA-induced mouse glaucoma model. Its integrated use of retinal markers, redox and iron measurements, transcript analysis, and protein assays provides a framework for evaluating how oxidative injury may limit cell-based retinal repair.

• WQ-C-401 Blocks PDGFR Signaling in Experimental PAH

  2026-09-20

  The reference study identifies WQ-C-401 as a selective PDGFR inhibitor that reduced pulmonary vascular remodeling, right ventricular hypertrophy, and hemodynamic abnormalities in monocrotaline-induced pulmonary arterial hypertension. Its combination of kinome profiling, cell-based signaling assays, and in vivo pathology provides a useful framework for evaluating PDGFR-directed interventions beyond oncology.

• Prochlorperazine Beyond Antiemesis: A Translational Map

  2026-09-19

  Prochlorperazine offers translational researchers a useful study model: a dopamine D2 receptor antagonist with antiemetic utility, broad receptor pharmacology, and emerging relevance to melanoma and antiviral research. This article connects mechanism, assay design, clinical safety, and evidence boundaries.

• ARCA Cy3 EGFP mRNA (5-moUTP) Workflow

  2026-09-18

  Use ARCA Cy3 EGFP mRNA (5-moUTP) to separate cellular uptake from productive translation in mammalian cell assays. Its covalent Cy3 label, EGFP reporter, ARCA cap, and 5-methoxyuridine modification support direct imaging, formulation screening, and reproducible delivery troubleshooting.

• Palbociclib (PD0332991) Cancer Research Workflows

  2026-09-18

  Build reproducible Palbociclib assays around Rb phosphorylation, DNA-content profiling, and apoptosis timing rather than relying on viability alone. The workflow also shows how to use CD109-driven colorectal cancer biology to formulate testable resistance hypotheses without confusing reference-study findings with established Palbociclib effects.

• TMEM16F Lipid Scrambling in Ferroptosis

  2026-09-17

  Yang et al. identify TMEM16F-mediated phospholipid scrambling as a late-stage suppressor of ferroptosis that protects the plasma membrane from lipid peroxide–driven collapse. The study links this membrane repair-like response to tumor progression and shows that inhibiting TMEM16F can improve tumor immune rejection when combined with PD-1 blockade.

• Moxifloxacin and the Next Logic of Gyrase Research

  2026-09-17

  Moxifloxacin is more than a broad-spectrum antibacterial tool: it is a translational probe for connecting gyrase inhibition with cellular stress, metabolic responses, and experimental design. This article places Moxifloxacin alongside mechanistic insights from gepotidacin research and outlines how to build better antibiotic toxicity and dose-response studies.

• Esculin in Renal Cell Carcinoma: Mechanistic Evidence

  2026-09-16

  This Biomolecules study combines network pharmacology, molecular docking, and cell-based validation to investigate how esculin affects renal cell carcinoma. The findings associate esculin with reduced RCC proliferation and migration, increased apoptotic responses, and inhibition of GAPDH-linked PI3K/Akt signaling, while also highlighting the need for in vivo and direct target-validation studies.

8498 records 1/567 page Next 12345 下5页 Last page